Cell expansion market seen reaching $69.42 billion by 2030

The Business Research Company projects the cell expansion market will grow from $37.54 billion in 2026 to $69.42 billion by 2030, driven by demand for cell and gene therapies, biologics manufacturing and regenerative medicine. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Cell expansion is a core process behind biopharmaceutical manufacturing, vaccine production and regenerative medicine. - The market’s expected growth signals rising demand for therapies that depend on scalable cell cultivation. - Faster adoption of closed systems, automated bioreactors and serum-free media could reshape how manufacturers expand cells at scale.

What happened: - The Business Research Company released its Cell Expansion Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report projects the cell expansion market will rise from $32.31 billion in 2025 to $37.54 billion in 2026. - The report forecasts the market will reach $69.42 billion by 2030. - The projected CAGR is 16.2% from 2025 to 2026 and 16.6% from 2026 to 2030.

The details: - The report links historical growth to expansion in biopharmaceutical manufacturing. - Increased use of mammalian cell cultures helped drive demand. - Cell expansion techniques saw broader use in vaccine production. - Research-scale cell cultivation added to market growth. - Wider availability of disposable culture systems supported adoption. - The forecast period is expected to benefit from rising demand for cell and gene therapies. - Investment in large-scale biologics manufacturing is another growth driver. - Regenerative medicine pipelines are expanding. - Manufacturers are focusing on cost-effective scale-up methods. - Closed-system expansion technologies are gaining adoption. - Key trends include greater use of single-use cell expansion systems. - Demand is increasing for scalable cell culture platforms. - Serum-free expansion media are being used more widely. - Automated bioreactor technologies are growing. - Process standardization is becoming a higher priority. - North America held the largest share of the cell expansion market in 2025. - Asia-Pacific is expected to post the fastest growth during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report defines cell expansion as the biological process in which new cell wall material is generated, allowing cells to loosen their walls and grow. - Proteins from the expansion family regulate wall loosening and cellular enlargement. - The report offers a free sample at Download a free sample of the report. - The full report is available View the full report.

Between the lines: - Government funding remains a key catalyst because public research dollars can accelerate cell-based therapy development and regenerative medicine work. - The report cites the National Cancer Institute’s fiscal 2023 budget of $7.3 billion, up $408 million from the prior year, as an example of public investment supporting the sector. - The combination of scale-up pressure and cost control suggests the market is shifting toward industrialized, repeatable production methods rather than smaller manual workflows.

What's next: - The strongest growth appears likely to come from companies building platforms for large-scale, closed and automated cell expansion. - Regions outside North America, especially Asia-Pacific, may see faster investment and manufacturing buildout. - The report says its 2026 editions include market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, hotspot infographics and updated graphics and tables.

The bottom line: - Cell expansion is moving from a supporting lab process to a larger commercial manufacturing opportunity, with growth tied to therapies that need reliable scale-up.